We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
-5.72%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$7.95B
AUM Growth
+$407M
Cap. Flow
+$737M
Cap. Flow %
9.28%
Top 10 Hldgs %
63.45%
Holding
409
New
72
Increased
88
Reduced
65
Closed
155

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$49.7M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$49.3M
3
IMCR icon
Immunocore
IMCR
+$41.4M
4
EXAS
Exact Sciences
EXAS
+$36.8M
5
IMVT icon
Immunovant
IMVT
+$35.1M

Top Sells

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$92.8M
2
KO icon
Coca-Cola
KO
+$36M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$31.9M
4
POST icon
Post Holdings
POST
+$26.8M
5
NOMD icon
Nomad Foods
NOMD
+$26.4M

Sector Composition

Rank Sector Weight
1 Healthcare 33.06%
2 Consumer Staples 5.21%
3 Consumer Discretionary 4.94%
4 Technology 3.72%
5 Materials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$2.12B 26.7%
3,900,000
+300,000
+8% +$157M
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$82.2B
$1.95B 24.51%
9,600,000
+800,000
+9% +$162M
PTCT icon
3
PTC Therapeutics
PTCT
$6.52B
$213M 2.68%
6,962,227
+198,227
+3% +$6.42M
SUPN icon
4
Supernus Pharmaceuticals
SUPN
$2.79B
$141M 1.77%
5,272,000
+1,700,000
+48% +$49.3M
NBIX icon
5
Neurocrine Biosciences
NBIX
$17.2B
$135M 1.69%
978,488
-45,251
-4% -$6.21M
CYTK icon
6
Cytokinetics
CYTK
$10.9B
$112M 1.41%
2,065,991
+540,303
+35% +$32.6M
INCY icon
7
Incyte
INCY
$23.4B
$107M 1.35%
1,764,000
-423,181
-19% -$24M
IMVT icon
8
Immunovant
IMVT
$8.27B
$89.7M 1.13%
3,396,909
+1,232,909
+57% +$35.1M
AGIO icon
9
Agios Pharmaceuticals
AGIO
$2.36B
$89.7M 1.13%
2,079,151
-884,849
-30% -$31.9M
ARGX icon
10
argenx
ARGX
$53.8B
$86M 1.08%
200,000
-64,000
-24% -$24.5M
NVO
11
Novo Nordisk
NVO
$223B
$77.7M 0.98%
544,000
+144,000
+36% +$19.1M
SNY icon
12
Sanofi
SNY
$107B
$72.8M 0.92%
1,500,000
+202,000
+16% +$9.74M
ALKS icon
13
Alkermes
ALKS
$8.79B
$65.1M 0.82%
2,699,179
+2,026,961
+302% +$49.7M
MDT icon
14
Medtronic
MDT
$106B
$64.9M 0.82%
824,511
+192,152
+30% +$15.8M
AUPH icon
15
Aurinia Pharmaceuticals
AUPH
$2.05B
$63.6M 0.8%
11,136,000
-1,124,000
-9% -$5.92M
TVTX icon
16
Travere Therapeutics
TVTX
$5.27B
$61.6M 0.78%
7,500,000
– –
EXAS
17
DELISTED
Exact Sciences
EXAS
$59.2M 0.74%
1,400,086
+669,438
+92% +$36.8M
GSK icon
18
GSK
GSK
$104B
$57.8M 0.73%
1,500,000
+536,000
+56% +$22.5M
XRAY icon
19
Dentsply Sirona
XRAY
$2.81B
$57.2M 0.72%
2,298,000
+550,945
+32% +$15.8M
CYTK icon
20
CALL
Cytokinetics
CYTK
$10.9B
$54.2M 0.68%
1,000,000
+300,000
+43% +$18.1M
SHAK icon
21
Shake Shack
SHAK
$2.34B
$52.2M 0.66%
579,904
+236,950
+69% +$23.1M
PENN icon
22
PENN Entertainment
PENN
$2.75B
$51.2M 0.64%
2,643,060
+1,266,023
+92% +$21.5M
IRWD icon
23
Ironwood Pharmaceuticals
IRWD
$635M
$50.9M 0.64%
7,800,000
+2,400,000
+44% +$17M
GRFS
24
Grifois
GRFS
$4.95B
$49.8M 0.63%
7,892,000
+1,244,000
+19% +$8.64M
OFIX icon
25
Orthofix Medical
OFIX
$468M
$49.7M 0.63%
3,750,000
+50,000
+1% +$685K
1
2 3 4 5

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.61B AUM 19.63% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
AIM
Alphinity Investment Management Sydney, Australia $5.68B AUM 26.72% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return

Armistice Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Armistice Capital held 409 positions worth $7.95B, up 5.4% from $7.54B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Armistice Capital deployed $737M of net new capital in Q2 2024, opening 72 new positions and adding to 88 existing holdings. Its largest new stake was Simply Good Foods: 957,163 shares worth $34.6M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 34% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Coca-Cola, an estimated $36M trimmed.

  • Armistice Capital's largest Q2 2024 buy was Simply Good Foods: 957,163 shares worth $34.6M.
  • Armistice Capital added most to Alkermes in Q2 2024, an estimated $49.7M increase.
  • Armistice Capital's biggest Q2 2024 reduction was Coca-Cola, cutting an estimated $36M.
  • Armistice Capital fully exited Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2024, selling an estimated $92.8M.
  • Armistice Capital's ten largest holdings make up 63% of its $7.95B portfolio in Q2 2024.
  • Armistice Capital opened 72 new positions and closed 155 in Q2 2024.
  • Armistice Capital's portfolio value rose 5.4% quarter-over-quarter to $7.95B.

Based on Armistice Capital's 13F filing for Q2 2024, filed 14 Aug 2024.